3ZLQ

BACE2 XAPERONE COMPLEX

Summary for 3ZLQ

• Entry DOI: 10.2210/pdb3zlq/pdb
• Descriptor: BETA-SECRETASE 2, XA4813, 5-Ethoxy-pyridine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide, ... (4 entities in total)
• Functional Keywords: hydrolase-immune system complex, hydrolase/immune system
• Biological source: HOMO SAPIENS (HUMAN); More
• Cellular location: Membrane; Single-pass type I membrane protein: Q9Y5Z0
• Total number of polymer chains: 4
• Total formula weight: 111216.50

Authors

Kuglstatter, A.,Stihle, M. (deposition date: 2013-02-04, release date: 2013-05-01, Last modification date: 2024-10-23)

Primary citation

Hilpert, H.,Guba, W.,Woltering, T.J.,Wostl, W.,Pinard, E.,Mauser, H.,Mayweg, A.V.,Rogers-Evans, M.,Humm, R.,Krummenacher, D.,Muser, T.,Schnider, C.,Jacobsen, H.,Ozmen, L.,Bergadano, A.,Banner, D.W.,Hochstrasser, R.,Kuglstatter, A.,David-Pierson, P.,Fischer, H.,Polara, A.,Narquizian, R.
Beta-Secretase (Bace1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer'S Disease.
J.Med.Chem., 56:3980-, 2013

PubMed Abstract: An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacological profile of this class of BACE1 inhibitors. The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF Aβ40 and 42 in rats at oral doses as low as 1 mg/kg. The effect was long lasting, showing a significant reduction of Aβ40 and 42 even after 24 h. In contrast to 89, compound 1b lacking the CF3 group was virtually inactive in vivo.

PubMed: 23590342
DOI: 10.1021/JM400225M

Experimental method

X-RAY DIFFRACTION (2.1 Å)